Interpreting International Real‐World Survival Outcomes After Avelumab First‐Line Maintenance in Advanced Urothelial Carcinoma: An RMST Analysis of Reconstructed Individual Patient Data

Abstract

Avelumab first‐line maintenance is an established treatment strategy for patients with advanced or metastatic urothelial carcinoma without progression after platinum‐based chemotherapy. Overall survival outcomes reported in international real‐world cohorts are difficult to compare because of differences in patient background, follow‐up duration, and later‐line treatment. We summarized these outcomes within a common time horizon.